Reliable Active Pharmaceutical Ingredient Manufacturer Supporting Global Healthcare

Ramelteon (CAS 196597-26-9) is a synthetic melatonin receptor agonist featuring a unique indeno-furan bicyclic scaffold fused to a propionamide side chain. The molecule is structurally derived from the endogenous hormone melatonin, with a rigid tricyclic framework that confers high affinity and selectivity for the MT₁ and MT₂ melatonin receptors.

Dronedarone (CAS 141626-36-0) is a non‑iodinated benzofuran derivative developed as a Class III antiarrhythmic agent for the management of paroxysmal and persistent atrial fibrillation. Structurally related to amiodarone, Dronedarone differs by the absence of iodine atoms, which eliminates the iodine‑associated thyroid and pulmonary toxicities that limit amiodarone’s long‑term use.

Dronedarone Hydrochloride (CAS 141625-93-6) is the hydrochloride salt form of dronedarone, a non-iodinated benzofuran derivative developed as a Class III antiarrhythmic agent for the treatment of atrial fibrillation. Structurally related to amiodarone, Dronedarone Hydrochloride lacks the iodine moieties that are associated with amiodarone-induced thyroid and pulmonary toxicity.

Ficonalkib (CAS 2233574-95-1) is a potent, selective, third-generation inhibitor of anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase implicated in various malignancies, particularly non-small cell lung cancer (NSCLC). The molecular structure of Ficonalkib (SY-3505) features a pyrrolo[2,3-d]pyrimidine core with a dimethylaminopiperidinyl substituent and a propan-2-ylsulfonylphenyl group.

Voxilaprevir (CAS 1535212-07-7) is a macrocyclic, reversible inhibitor of the hepatitis C virus (HCV) NS3/4A serine protease. Developed by Gilead Sciences, Voxilaprevir is a fluorinated macrocyclic compound featuring a complex pentacyclic scaffold with a molecular formula of C₄₀H₅₂F₄N₆O₉S. The structure of Voxilaprevir incorporates a difluoromethyl cyclopropyl sulfonylcarbamoyl moiety and a tert-butyl group, which together contribute to its high-affinity binding to the NS3/4A protease active site.

Bictegravir (CAS 1611493-60-7) is a second-generation HIV-1 integrase strand transfer inhibitor (INSTI) developed by Gilead Sciences. Chemically, it is a monocarboxylic acid amide derivative featuring a complex polycyclic core that incorporates a pyrimidine ring, a quinoline ring, and a tetrahydrofuran ring. The molecular structure of Bictegravir is characterized by a rigid, tricyclic scaffold that extends residence time on the integrase-DNA complex, a property that underpins its exceptional potency against HIV-1 strains resistant to earlier integrase inhibitors such as raltegravir, elvitegravir, and dolutegravir.